Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation
- PMID: 23208833
- DOI: 10.1002/phar.1151
Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation
Abstract
Study objective: To investigate oseltamivir and oseltamivir carboxylate pharmacokinetics in critically ill patients who were receiving continuous venovenous hemodialysis (CVVHD) and/or extracorporeal membrane oxygenation (ECMO).
Design: Prospective, open-label, pharmacokinetic study.
Setting: Intensive care units of an academic medical center.
Patients: Thirteen critically ill patients aged 13 years or older with suspected or confirmed H1N1 influenza who had a prescription for oseltamivir and were concurrently receiving CVVHD and/or ECMO between October 2009 and January 2010.
Intervention: Oseltamivir 150 mg was administered nasogastrically or nasoenterically every 12 hours. Blood samples were collected at baseline and at 1, 2, 4, 6, 8, 10, and 12 hours after administration of the fourth oseltamivir dose or subsequent doses. In patients receiving CVVHD, effluent also was collected at the same time points. Urine was collected throughout the 12-hour dosing interval.
Measurements and main results: Eight patients received CVVHD only, four patients received both CVVHD and ECMO, and one patient received ECMO only. Pharmacokinetic parameters for the patient who received only ECMO were not reported. The median maximum plasma concentration and area under the plasma concentration-time curve for the 12-hour dosing interval (AUC(0-12) ) for the remaining 12 patients were 83.4 ng/ml and 216 ng•hour/ml, respectively, for oseltamivir and 2000 ng/ml and 21,500 ng•hour/ml, respectively, for oseltamivir carboxylate. Mean clearance due to CVVHD was 33.8 ml/minute for oseltamivir and 50.2 ml/minute for oseltamivir carboxylate. For patients who received ECMO, no substantial differences between pre- and post-ECMO oxygenator plasma concentrations were found for oseltamivir or oseltamivir carboxylate.
Conclusion: Although the optimal pharmacokinetic-pharmacodynamic targets for oseltamivir carboxylate remain unclear, in the patients receiving CVVHD with or without ECMO, a regimen of oseltamivir 150 mg every 12 hours yielded a median oseltamivir carboxylate AUC(0-12) considerably higher than would be expected in non-critically ill patients receiving the same dosage regimen.
Trial registration: ClinicalTrials.gov NCT01048879.
© 2012 Pharmacotherapy Publications, Inc.
Similar articles
-
Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.Anaesth Intensive Care. 2013 Jan;41(1):66-73. doi: 10.1177/0310057X1304100112. Anaesth Intensive Care. 2013. PMID: 23362894 Clinical Trial.
-
Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.Ther Drug Monit. 2012 Apr;34(2):171-5. doi: 10.1097/FTD.0b013e318248672c. Ther Drug Monit. 2012. PMID: 22354159
-
The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis.J Pediatr Pharmacol Ther. 2012 Apr;17(2):173-6. doi: 10.5863/1551-6776-17.2.173. J Pediatr Pharmacol Ther. 2012. PMID: 23118670 Free PMC article.
-
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Clin Pharmacokinet. 2010 Nov;49(11):741-65. doi: 10.2165/11534730-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20923248 Review.
-
Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients.J Clin Pharm Ther. 2017 Dec;42(6):661-671. doi: 10.1111/jcpt.12636. Epub 2017 Sep 25. J Clin Pharm Ther. 2017. PMID: 28948652 Review.
Cited by
-
Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs.J Clin Med. 2023 May 29;12(11):3748. doi: 10.3390/jcm12113748. J Clin Med. 2023. PMID: 37297946 Free PMC article. Review.
-
Successful Treatment of Complicated Influenza A(H3N2) Virus Infection and Rhabdomyolysis with Compassionate Use of IV Zanamivir.Pharmaceuticals (Basel). 2023 Jan 7;16(1):85. doi: 10.3390/ph16010085. Pharmaceuticals (Basel). 2023. PMID: 36678583 Free PMC article.
-
Antiviral Drugs in Influenza.Int J Environ Res Public Health. 2022 Mar 4;19(5):3018. doi: 10.3390/ijerph19053018. Int J Environ Res Public Health. 2022. PMID: 35270708 Free PMC article. Review.
-
Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Adults During Extracorporeal Membrane Oxygenation: A Systematic Review.Drugs. 2021 Jul;81(11):1307-1329. doi: 10.1007/s40265-021-01557-3. Epub 2021 Jul 5. Drugs. 2021. PMID: 34224115
-
Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.Front Pharmacol. 2020 May 29;11:786. doi: 10.3389/fphar.2020.00786. eCollection 2020. Front Pharmacol. 2020. PMID: 32547394 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical